Insider Selling: Artivion (NYSE:AORT) SVP Sells $81,189.22 in Stock

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 2,149 shares of Artivion stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $81,189.22. Following the completion of the transaction, the senior vice president directly owned 60,097 shares of the company’s stock, valued at approximately $2,270,464.66. This represents a 3.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Artivion Stock Down 1.8%

Shares of NYSE:AORT opened at $37.18 on Friday. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of 185.91 and a beta of 1.60. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.25. The company’s fifty day moving average is $41.06 and its two-hundred day moving average is $42.84. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The business had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. Artivion’s revenue for the quarter was up 19.2% compared to the same quarter last year. Equities analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on AORT. Citizens Jmp upped their target price on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Stifel Nicolaus set a $55.00 target price on shares of Artivion in a research report on Thursday. Oppenheimer reiterated an “outperform” rating and set a $50.00 target price on shares of Artivion in a research note on Friday, November 7th. Finally, Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Artivion has an average rating of “Moderate Buy” and a consensus target price of $50.47.

Hedge Funds Weigh In On Artivion

Hedge funds have recently modified their holdings of the stock. Verition Fund Management LLC increased its holdings in shares of Artivion by 1.6% during the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock worth $716,000 after buying an additional 274 shares in the last quarter. Entropy Technologies LP boosted its holdings in shares of Artivion by 6.0% in the 4th quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock worth $251,000 after acquiring an additional 310 shares in the last quarter. State of Alaska Department of Revenue grew its position in Artivion by 1.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company’s stock worth $985,000 after acquiring an additional 414 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in Artivion by 6.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock valued at $349,000 after purchasing an additional 477 shares in the last quarter. Finally, Arizona State Retirement System raised its position in Artivion by 4.6% in the 4th quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock valued at $512,000 after purchasing an additional 494 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.